Richard Davis
Director/Board Member at NANEXA AB
Profile
Richard Jon Davis is currently an Independent Director at Nanexa AB since 2022 and the Chief Operating Officer at Nouscom AG since 2020.
Previously, he served as the Chief Executive Officer at Trino Therapeutics Ltd.
from 2014 to 2015.
He also held a position as a Non-Executive Director at Kymab Ltd.
and worked as a Manager-Healthcare Investment at The Wellcome Trust Ltd.
Dr. Davis obtained his undergraduate and doctorate degrees from the University of Leicester.
Richard Davis active positions
Companies | Position | Start |
---|---|---|
NANEXA AB | Director/Board Member | 2021-12-31 |
Nouscom AG
Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland. | Chief Operating Officer | 2022-05-22 |
Former positions of Richard Davis
Companies | Position | End |
---|---|---|
Trino Therapeutics Ltd.
Trino Therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Trino Therapeutics Ltd. operates as a drug discovery and development company. It focuses on developing oral small molecules for the treatment and unmet management of inflammatory bowel disease and other inflammatory indications. The company was founded by Neil Howard Frankish and Helen Sheridan in 1999 and is headquartered in Dublin, Ireland. | Chief Executive Officer | - |
The Wellcome Trust Ltd.
The Wellcome Trust Ltd. Investment Trusts/Mutual FundsMiscellaneous The Wellcome Trust Ltd. engages welfare and charitable services. It supports the discovery of vaccines and drug-resistant infections, diversity and inclusion, open research, government investment in research, data sharing in public health emergencies, and strengthening ecosystems. The company was founded by Henry Wellcome in 1936 and is headquartered in London, UK. | Corporate Officer/Principal | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Director/Board Member | - |
Training of Richard Davis
University of Leicester | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
NANEXA AB | Health Technology |
Private companies | 4 |
---|---|
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Trino Therapeutics Ltd.
Trino Therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Trino Therapeutics Ltd. operates as a drug discovery and development company. It focuses on developing oral small molecules for the treatment and unmet management of inflammatory bowel disease and other inflammatory indications. The company was founded by Neil Howard Frankish and Helen Sheridan in 1999 and is headquartered in Dublin, Ireland. | Health Technology |
The Wellcome Trust Ltd.
The Wellcome Trust Ltd. Investment Trusts/Mutual FundsMiscellaneous The Wellcome Trust Ltd. engages welfare and charitable services. It supports the discovery of vaccines and drug-resistant infections, diversity and inclusion, open research, government investment in research, data sharing in public health emergencies, and strengthening ecosystems. The company was founded by Henry Wellcome in 1936 and is headquartered in London, UK. | Miscellaneous |
Nouscom AG
Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland. | Health Technology |
- Stock Market
- Insiders
- Richard Davis